Wednesday, July 27, 2022
| Wednesday, July 27, 2022 | |
|---|---|
| 8:00 am – 5:00 pm | Poster Hall Setup |
| 9:00 am – 8:30 pm | Registration Opens |
| 6:00 pm – 7:00 pm | Welcome and Opening Remarks Lifetime Achievement Award Ceremony and Presentations |
| 7:00 pm – 9:00 pm | Welcome Reception Poster Hall Open |
| Thursday, July 28, 2022 | |
|---|---|
| 7:30 am – 6:30 pm | Registration/Information |
| 7:30 am – 8:30 am | Breakfast Poster Hall Open |
| 8:30 am – 12:00 noon | Carondelet Room on 3rd Floor Plenary Session Chair: Alberto Esquenazi, MD (USA) |
| 8:30 am – 8:45 am | Opening Remarks |
| 8:45 am – 9:30 am | Engineering Bacterial Toxins Into Therapeutics Keynote Speaker: Min Dong, PhD (USA) |
| 9:30 am – 10:00 am | Focus on BoNT Engineering (Phage–Assisted Evolution of Botulinum Neurotoxin Proteases With Reprogrammed Specificity) Travis Blum, PhD (USA) |
| 10:00 am – 10:30 am | Basis of Movement Control and Why Botulinum Toxin Should Influence It Aparna Wagle Shukla, MD (USA) |
| 10:30 am – 11:00 am | Break Poster Hall Open |
| 11:00 am – 12:00 noon | Botulinum Toxin in the COVID Era: Issues and Challenges Moderator: Barbara Karp, MD (USA) Chris Boulias, MD, PhD (Canada) Francisco Cardoso, MD (Brazil) David Simpson, MD (USA) |
| 12:00 noon – 2:00 pm | Lunch Poster Hall Open |
| Time | Basic Science Track Balcony K 4th Floor |
Time | Clinical Track 1A Balcony M & L 4th Floor |
Time | Clinical Track 2A Salon E 3rd Floor |
Time | Clinical Track 3A Balcony I & J 4th Floor |
Time | Clinical Track 4A Salon D 3rd Floor |
Time | Clinical Track 5A Salon H 3rd Floor |
|||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2:00 pm – 3:35 pm | History, Genetics, and Evolution Chair: Ornella Rossetto, PhD (Italy) Co-Chair: Sabine Pellett, PhD (USA) |
2:00 pm – 3:35 pm | Adult Spasticity I Chair: Alberto Esquenazi, MD (USA) |
2:00 pm – 3:30 pm | Cervical Dystonia Chair: Alberto Albanese, MD (Italy) |
2:00 pm – 3:35 pm | Selected Topics I Chair: Francisco Cardoso, MD (Brazil) |
2:00 pm – 3:35 pm | Aesthetic Medicine and Dermatology Chair: Steven Yoelin, MD (USA) |
2:00 pm – 3:30 pm | Genitourinary Botulinum Toxin Applications Chair: Roger Dmochowski, MD (USA) |
|||||
| 2:00 pm – 2:20 pm | Geographical Distribution of Clostridium botulinum Phyla Carolina Luquez, PhD (USA) |
2:00 pm – 2:25 pm | What's New? BoNT Clinical Trial Update: Adult Spasticity Gerard Francisco, MD (USA) |
2:00 pm – 2:25 pm | What's New? BoNT Clinical Trial Update: Cervical Dystonia Cynthia Comella, MD (USA) |
2:00 pm – 2:30 pm | Botulinum Toxin in Parkinsonian Disorders Robert Chen, MD (Canada) |
2:00 pm – 2:40 pm | Essential Anatomy and InjectionTechnique: Neuromodulators for Aesthetic Use in the Upper, Mid and Lower Face Wendy Lee, MD, MS (USA) Steven Yoelin, MD (USA) |
2:00 pm – 2:30 pm | Update on the Management of Overactive Bladder Dudley Robinson, MBBS, MD, FRCOG (UK) |
|||||
| 2:20 pm – 2:40 pm | Chromosomally Integrated Plasmids in G1 C. botulinum Kristin Schill, PhD (USA) |
2:25 pm – 2:50 pm | Gait Pattern Recognition and Muscle Selection for BoNT Injections Alberto Esquenazi, MD (USA) |
2:25 pm – 2:50 pm | Anatomy and Ultrasound-Guided Injection of Deep Neck Muscles for Anterocollis Katharine Alter, MD (USA) |
2:30 pm – 3:00 pm | Use of Kinematic Analysis for Individualized Botulinum Toxin Treatment Mandor Jog, MD (Canada) |
2:40 pm – 3:10 pm | Clinical Implications of the Long-Term Use of Neuromodulators for Aesthetic Indications Michael Kane, MD (USA) |
2:30 pm – 3:00 pm | Applications of Botulinum Toxin: The Female Pelvic Floor Barbara Karp, MD (USA) |
|||||
| 2:40 pm – 3:35 pm | Round Table: Bacterial Nomenclature in the Genomic Era—Considerations of Nomenclature Changes of Clostridium botulinum 1. Bacterial Nomenclature Rules and Implications of Classification Changes of Bacteria of Medical Importance Marc Allard, PhD (USA) 2. Botulinum Neurotoxins Producing Bacteria in the Genomic Era Theresa J. Smith, MS (USA) 3. Implications of Re-classification of C. botulinum From the Public Health Perspective Carolina Luquez, PhD (USA) |
2:50 pm – 3:10 pm | What Are We Missing? It’s More Than Injections Laura Wiggs, PT, NCS, CBIS (USA) |
2:50 pm – 3:15 pm | Functional or Psychogenic Dystonia: Should We Inject BoNT? Alberto Albanese, MD (Italy) |
3:00 pm - 3:30 pm | Effects of Toxin on Non-Motor Symptoms in Dystonia H. A. Jinnah, MD (USA) |
3:10 pm - 3:25 pm | OnabotulinumtoxinA for Treatment of Masseter Muscle Prominence and Masseter Muscle Hypertrophy: Results From Phase 2 Studies Jason Rivers, MD (Canada) |
3:00 pm - 3:30 pm | The Urinary Tract and Neurotoxin Roger Dmochowski, MD (USA) |
|||||
| 3:10 pm - 3:35 pm | What Are the Early Risk Factors for Disabling Spasticity—Does BoNT Treatment Reduce the Risk Effectively? Anthony Ward, MBE, BSc, MD, FRCP (UK) |
3:15 pm - 3:30 pm | A Phase 3 Trial Evaluating the Efficacy, Duration of Effect, and Safety of DaxibotulinumtoxinA for Injection in the Treatment of Cervical Dystonia Cynthia Comella, MD (USA) |
3:25 pm - 3:35 pm | Subject Satisfaction With AbobotulinumtoxinA for Moderate-to-Severe Glabellar Lines: A Randomized, Dose-Escalating, Double-Blind Study Amir Moradi, MD (USA) |
|||||||||||
| 3:35 pm – 3:55 pm | Break Poster Hall Open |
3:35 pm – 3:55 pm | Break Poster Hall Open |
3:35 pm – 3:55 pm | Break Poster Hall Open |
3:35 pm – 3:55 pm | Break Poster Hall Open |
3:35 pm – 3:55 pm | Break Poster Hall Open |
|||||||
| Time | Basic Science Track Balcony K 4th Floor |
Time | Clinical Track 1B Balcony M & L 4th Floor |
Time | Clinical Track 2B Salon E 3rd Floor |
Time | Clinical Track 3B Balcony I & J 4th Floor |
Time | Injection Demonstration Workshop 4B Salon D 3rd Floor |
|||||||
| 3:55 pm – 5:15 pm | Toxin Engineering and Pharmacokinetics Chair: Andreas Rummel, PhD (Germany) Co-Chair: Michel Popoff, PhD (France) |
3:55 pm – 5:20 pm | Oromandibular Dystonia, Spasmodic Dysphonia, Blepharospasm, and Meige Syndrome Chair: Andrew Blitzer, MD, DDS (USA) |
3:55 pm – 5:30 pm | Practical Considerations and Selected Abstracts Chair: Chris Boulias, MD, PhD (Canada) |
3:55 pm – 5:25 pm | Pediatric Spasticity Chair: Katharine Alter, MD (USA) |
3:55 pm – 5:30 pm | Aesthetic Medicine and Dermatology: Round Robin Injection Workshop Chair: Deirdre Hooper, MD (USA) |
|||||||
| 3:55 pm – 4:15 pm | Botulinum Neurotoxin Trafficking Within Motor Neurons Patrick M. McNutt, PhD (USA) |
3:55 pm – 4:15 pm | Spasmodic Dysphonia Andrew Blitzer, MD, DDS (USA) |
3:55 pm – 4:25 pm | Clinical Aspects Associated With BoNT Properties: Does Altering the Onset of Action and Increasing Duration of Action Really Matter in Clinical Practice? Sarah Pirio Richardson, MD (USA) |
3:55 pm – 4:35 pm | How Do We Optimize Outcomes in Pediatric Patients? BoNT Selection, Guidance Methods, Sedation vs No Sedation Katharine Alter, MD (USA) |
3:55 pm – 5:30 pm | Round Robin Injection Workshop Julie Bass-Kaplan, FNP-BC, MSN, CANS (USA) Deirdre Hooper, MD (USA) Wendy Lee, MD, MS (USA) Haley Wood, WHNP, MSN, CANS (USA) Glenn Vallecillos, MD (USA) Steve Yoelin, MD (USA) |
|||||||
| 4:15 pm – 4:35 pm | Engineering BoNTs as Vehicles for Drug Delivery/Neuronal Delivery Vehicles Using Antibodies for BoNT Intoxication Konstantin Ichtchenko, PhD (USA) |
4:15 pm – 4:35 pm | What's New? BoNT Clinical Trial Update: Oromandibular Dystonia Nikita Kohli, MD (USA) |
4:25 pm – 4:55 pm | Dosing Intervals With BoNT: Managing Multiple Indications and Boosters David Simpson, MD (USA) |
|||||||||||
| 4:35 pm – 4:45 pm | Immunostaining Procedure for Ganglioside Expression Evaluation in Human Neurons Sylvain Roqueviere, PhD (France) |
4:35 pm – 5:05 pm | To Treat or Not to Treat the Pediatric Patient With BoNT: Are There Long-Term Consequences? Mark Gormley, MD (USA) |
|||||||||||||
| 4:45 pm – 4:55 pm | Cell-Penetrating Peptides: Are They Useful Excipients in Botulinum Toxin Formulations? James Austerberry, PhD (UK) |
4:35 pm – 4:55 pm | Oromandibular Dystonia: A Clinical Examination of 2,020 Cases H. A. Jinnah, MD (USA) |
|||||||||||||
| 4:55 pm – 5:05 pm | Resolution of Two Steps in Botulinum Neurotoxin Serotype A1 Light Chain Localization to the Intracellular Plasma Membrane Alex Gardner, BS (USA) |
4:55 pm – 5:20 pm | How to Adjust Expectations and Manage a Newly-Diagnosed Blepharospasm and Meige Syndrome Patient Barbara Karp, MD (USA) |
4:55 pm - 5:10 pm | IncobotulinumtoxinA for Refractory Neuropathic Pain Following Breast Cancer Surgery Eric J. Viel, MD, PhD (France) |
5:05 pm – 5:25 pm | Spasticity-Related Pain in Children/Adolescents With Cerebral Palsy Florian Heinen, MD (Germany) |
|||||||||
| 5:10 pm - 5:20 pm | Current Perspectives on the Management of Cervical Dystonia Among Global Clinicians Stephanie Standal, MD (USA) |
|||||||||||||||
| 5:05 pm – 5:15 pm | Analgesic Activity of AbobotulinumtoxinA in Postoperative Pain Models in the Pig Is Driven by the Route of Administration: New Highlights on the Mechanism of Action Stephane Lezmi, PhD (France) |
5:20 pm - 5:30 pm | Comparison of Ultrasound and Electrical Stimulation Guidance for Botulinum Neurotoxin Injections: A Randomized Cross-Over Study David Simpson, MD (USA) |
| Friday, July 29, 2022 | |
|---|---|
| 7:15 am – 8:15 am | INA Business Meeting |
| 7:15 am – 6:30 pm | Registration/Information |
| 7:30 am – 8:30 am | Breakfast Poster Hall Open |
| 8:30 am – 12:00 noon | Carondelet Room on 3rd Floor Plenary Session Chair: Giampietro Schiavo, PhD (UK) |
| 8:30 am – 8:40 am | Welcome Back Chair: Giampietro Schiavo, PhD (UK) |
| 8:40 am – 9:05 am | BoNT as a Treatment Option for Age-Related Macular Degeneration Gary Borodic, MD (USA) |
| 9:05 am – 9:35 am | Antipruritic Effect of BoNTs Parisa Gazerani, PharmD, PhD (Denmark) |
| 9:35 am – 10:05 am | BoNT in the Management of Neuropathic Pain Nadine Attal, MD, PhD (France) |
| 10:05 am – 10:30 am | The Emerging Role of Botulinum Toxin in Cardiology Jonathan S. Steinberg, MD (USA) |
| 10:30 am – 11:00 am | Break Poster Hall Open |
| 11:00 am – 12:00 noon | Depression Roundtable: Is There a Role for BoNT? Moderator: Alberto Albanese, MD (Italy) Nicholas A. Coles, PhD (USA) Eric Finzi, MD, PhD (USA) Lori Kels, MD, MPH (USA) |
| 12:00 noon – 2:00 pm | Lunch Poster and Exhibit Hall Open |
| Time | Basic Science Track Balcony K 4th Floor |
Time | Injection Workshop 1A Carondelet 3rd Floor |
Time | Clinical Track 2A Balcony I & J 4th Floor |
Time | Clinical Track 3A Salon D 3rd Floor |
Time | Clinical Track 4A Salon E 3rd Floor |
||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2:00 pm – 3:20 pm | BoNT Detection and Countermeasures Chair: Patrick McNutt, PhD (USA) |
2:00 pm – 3:35 pm | Injection Demonstration Workshop Pediatric Spasticity Chair: Katharine Alter, MD (USA) |
2:00 pm – 3:35 pm | Headache and Pain Chair: Cristina Tassorelli, MD (Italy) |
2:00 pm – 3:35 pm | Aesthetic Medicine and Dermatology Chair: Nowell Solish, MD (Canada) |
2:00 pm – 3:35 pm | Adult Spasticity II Chair: Anthony Ward, MBE, BSc, MD, FRCP (UK) |
||||
| 2:00 pm – 2:20 pm | Detection of Select Agent Toxins in Support of Public Health Activities Suzy Kalb, PhD (USA) |
2:00 pm – 3:35 pm | Pediatric Spasticity Ann Tilton, MD (USA) |
2:00 pm – 2:25 pm | BoNT for Suppression of Chronic Migraine: What Have We Learned in 10+ Years? Peter McAllister, MD (USA) |
2:00 pm – 2:30 pm | Update on Hyperhidrosis Dee Anna Glaser, MD (USA) |
2:00 pm – 2:30 pm | Balancing Dosing in Patients Who Need More Than You Can Give Cindy Ivanhoe, MD (USA) |
||||
| 2:20 pm – 2:40 pm | Monoclonal Antibody Combinations for the Prevention and Treatment of Botulism Jim Marks, PhD (USA) |
2:25 pm – 2:45 pm | Potential Use of BoNT in Treating Other Primary Headache Disorders and Facial Pain Cristina Tassorelli, MD (Italy) |
2:30 pm – 3:05 pm | Micro Toxin Technique: What, Why, and Where? Woffles Wu, MBBS, FRCS, FAMS (Singapore) |
2:30 pm – 3:00 pm | Early vs Late BoNT Management of Post-Stroke Spastic Movement Disorder Jörg Wissel, MD (Germany) |
||||||
| 2:40 pm – 3:00 pm | Fabs From Purified HumAbs Open to the Intrathecal Therapy of Tetanus Marco Pirazzini, PhD (Italy) |
2:45 pm – 3:05 pm | BoNT, mAbs, and Gepants: Elegant Synergism or Expensive Redundancy? Peter McAllister, MD (USA) |
||||||||||
| 3:00 pm – 3:10 pm | Novel, Genetically Engineered SNAP-25 Reporter Constructs for BoNT-A and BoNT-E Toxin Activity Measurement Kimia Hosseini, PhD (Sweden) |
3:05 pm – 3:15 pm | Real-World Safety and Efficacy of 156-195 U OnabotulinumtoxinA in Participants With Chronic Migraine: Results From the REPOSE Study Katherine Sommer, MRes, PhD (USA) |
3:05 pm – 3:15 pm | Subject Satisfaction With Two Treatments Per Year (Every Six Months) of AbobotulinumtoxinA Is High Among Both Previously Treated and Toxin-naïve Cohorts Sarah Coquis-Knezek, PhD (USA) |
3:00 pm – 3:25 pm | Guided Self-Rehabilitation Combined With BoNT in Adults With Spastic Paresis Jean-Michel Gracies, MD (France) |
||||||
| 3:10 pm – 3:20 pm | Screening and Development of 9-Hydroxy-4H-Pyrido[1,2-a]Pyrimidin-4-One–Based Bifunctional Inhibitors of BoNT-A/LC Ealin Patel, PhD (USA) |
3:15 pm – 3:25 pm | Real-world Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients With Chronic Migraine Jennifer W. McVige, MD, MA, FASN (USA) |
3:15 pm - 3:35 pm | The Air Toxin Technique: Introduction and Analysis of Effect Using a Photo Imaging System Hei Sung Kim, MD (South Korea) |
||||||||
| 3:25 pm – 3:35 pm | Consecutive Headache-Free Days With OnabotulinumtoxinA Treatment in Patients With Chronic Migraine: A Pooled PREEMPT Analysis Katherine Sommer, MRes, PhD (USA) |
3:25 pm - 3:35 pm | The Impact of Isokinetic Lower Limb Muscle Strengthening Associated With Focal Spasticity Treatment on the Endurance, Strength, and Quality of Life of Multiple Sclerosis Patients Hadjira Aboura, MD (Algeria) |
||||||||||
| 3:35 pm - 3:55 pm | Break Poster Hall Open |
3:35 pm - 3:55 pm | Break Poster Hall Open |
3:35 pm - 3:55 pm | Break Poster Hall Open |
3:35 pm - 3:55 pm | Break Poster Hall Open |
3:35 pm - 3:55 pm | Break Poster Hall Open |
||||
| Time | Basic Science Track Balcony K 4th Floor |
Time | Injection Demonstration Workshop 1B Carondelet 3rd Floor |
Time | Clinical Track 2B Balcony I & J 4th Floor |
Time | Clinical Track 3B Salon D 3rd Floor |
Time | Clinical Track 4B Salon E 3rd Floor |
||||
| 3:55 pm – 5:25 pm | Structural and Functional Aspects of BoNTs Chair: Suzy Kalb, PhD (USA) Co-Chair: Sabine Pellett, PhD (USA) |
3:55 pm – 5:30 pm | Injection Demonstration Workshop - Cervical Dystonia and Oromandibular Dystonia and Adult Spasticity Chairs: Cynthia Comella, MD (USA) & Anthony Ward, MBE, BSc, MD, FRCP (UK) |
3:55 pm – 5:20 pm | Selected Topics II Chair: Robert Chen, MD (Canada) |
3:55 pm – 5:10 pm | Aesthetic Medicine and Dermatology Chair: Michael Kane, MD (USA) |
3:55 pm – 5:30 pm | Sialorrhea, Tics, Tremor, and Focal Limb Dystonia Chair: David Simpson, MD (USA) |
||||
| 3:55 pm – 4:15 pm | Are Non-Clostridial Homologs Botulinum Neurotoxins? Travis Wentz, MHS (USA) |
3:55 pm – 4:45 pm | Cervical Dystonia and Oromandibular Dystonia Sarah Perez, MD (USA) |
3:55 pm – 4:20 pm | Changes in Cortical Excitability and Plasticity After Botulinum Toxin Injection Robert Chen, MD (Canada) |
3:55 pm – 4:30 pm | The Use of Neuromodulators for Facial Shaping Woffles Wu, MBBS, FRCS, FAMS (Singapore) |
3:55 pm – 4:20 pm | BoNT Clinical Trial Update: Sialorrhea Mark Lew, MD (USA) |
||||
| 4:15 pm – 4:35 pm | Recognition of the Protein Receptor SV2 by BoNTs Andreas Rummel, PhD (Germany) |
4:20 pm – 4:45 pm | Parkinsonism: Is There a Place for BoNT Management of Posture, Rigor, Tremor, and Mobility? Charenya Anandan, MD (USA) |
4:30 pm – 5:10 pm | Neuromodulators From Around the World: What’s Here and What’s to Come Nowell Solish, MD (Canada) |
4:20 pm – 4:50 pm | Laryngeal Tremor, Myoclonus, and Tics: Is There a Role for BoNT? Andrew Blitzer, MD, DDS (USA) |
||||||
| 4:35 pm – 4:55 pm | Structure and Activity of Botulinum Neurotoxin X Paul Stenmark, PhD (Sweden) |
4:45 pm – 5:30 pm | Adult Spasticity Andrea Toomer, MD (USA) |
4:45 pm – 5:10 pm | Clinical Profile of BoNT Response/Immunogenicity Philipp Albrecht, MD (Germany) |
4:50 pm – 5:15 pm | Focal Limb Dystonia and Tremor: A Look at the BoNT Data Codrin Lungu, MD (USA) |
||||||
| 4:55 pm – 5:15 pm | Botulinum Neurotoxin/A Light Chain Interactions with Neurons Joseph Barbieri, PhD (USA) |
5:10 pm - 5:20 pm | Applicability of Botulinum Toxin in Treatment of Holmes Tremor, Our Cases and Detailed Review of Current Literature Eshita Shah, MD (USA) |
5:15 pm – 5:30 pm | Musician’s Focal Limb Dystonia: Results of a Placebo-Controlled Study David Simpson, MD (USA) |
||||||||
| 5:15 pm – 5:25 pm | Botulinum Neurotoxin Accelerates the Resolution of Bacterial Skin Infections in Mice Liwen Deng, PhD (USA) |
| Saturday, July 30, 2022 | |
|---|---|
| 7:30 am – 12:00 noon | Information |
| 8:00 am – 9:00 am | Breakfast Poster and Exhibit Hall Open |
| 9:00 am – 11:30 am | Plenary Session Carondelet |
| 9:00 am – 9:10 am | Welcome Back Chair: David Simpson, MD (USA) |
| 9:10 am – 9:55 am | Questions About BoNT You Were Afraid to Ask Moderator: David Simpson, MD (USA) Cindy Ivanhoe, MD (USA) Andreas Rummel, PhD (Germany) Giampietro Schiavo, PhD (UK) Nowell Solish, MD (Canada) Katharine Alter, MD (USA) |
| 9:55 am – 10:25 am | A Look at the Future—New BoNTs and Delivery Systems in Development: A View From the Bench Sabine Pellett, PhD (USA) |
| 10:25 am – 10:55 am | A Look at the Future—New BoNTs and Delivery Systems in Development: What It Could Mean in the Clinic Ryuji Kaji, MD (Japan) |
| 10:55 am – 11:10 am | Best Clinical Abstract |
| 11:10 am – 11:25 am | Best Basic Science Abstract |
| 11:25 am – 11:30 am | Closing Remarks David Simpson, MD (USA) |